{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T11:41:55Z","timestamp":1781005315819,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clbc.2024.11.006","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T13:38:22Z","timestamp":1731505102000},"page":"164-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Yoonwon","family":"Kook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Soo","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soong June","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Ho","family":"Baek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joon Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Seung","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jai Min","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8778-9686","authenticated-orcid":false,"given":"Sung Gwe","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.11.006_bib0001","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after Adjuvant chemotherapy in HER2-positive breast cancer. New Eng J Med. 2005;353:1659\u20131672. https:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa052306?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200www.ncbi.nlm.nih.gov. Accessed Mar 30 2024."},{"key":"10.1016\/j.clbc.2024.11.006_bib0002","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1007\/s40265-013-0109-0","article-title":"Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer","volume":"73","author":"McCormack","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.clbc.2024.11.006_bib0003","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.3174\/ajnr.A2619","article-title":"Trastuzumab (herceptin)","volume":"32","author":"Gemmete","year":"2011","journal-title":"AJNR Am J Neuroradiol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0004","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1158\/0008-5472.CAN-08-4597","article-title":"Strongly enhanced antitumor activity of Trastuzumab and Pertuzumab combination treatment on HER2-positive Human xenograft tumor models","volume":"69","author":"Scheuer","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.clbc.2024.11.006_bib0005","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(11)70336-9","article-title":"Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial","volume":"13","author":"Gianni","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0006","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S1470-2045(18)30570-9","article-title":"Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"van Ramshorst","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0007","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","article-title":"Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)","volume":"24","author":"Schneeweiss","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0008","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clbc.2024.11.006_bib0009","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1703643","article-title":"Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer","volume":"377","author":"von Minckwitz","year":"2017","journal-title":"New Eng J Med"},{"key":"10.1016\/j.clbc.2024.11.006_bib0010","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.annonc.2022.06.009","article-title":"VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up","volume":"33","author":"Loibl","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0011","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1001\/jamaoncol.2022.2310","article-title":"Response rate and safety of a neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab regimen for patients with ERBB2-positive stage II\/III breast cancer: the Neo-PATH phase 2 nonrandomized clinical trial","volume":"8","author":"Ahn","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0012","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(17)30716-7","article-title":"Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial","volume":"19","author":"Hurvitz","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0013","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1200\/JCO.19.00882","article-title":"Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human epidermal growth factor receptor 2-positive breast cancer: three-year outcomes from the phase III KRISTINE study","volume":"37","author":"Hurvitz","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0014","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s10549-021-06137-3","article-title":"Recurrence rates in patients with HER2+ breast cancer who achieved a pathological complete response after neoadjuvant pertuzumab plus trastuzumab followed by adjuvant trastuzumab: a real-world evidence study","volume":"187","author":"O'Shaughnessy","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.11.006_bib0015","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1200\/JCO.20.00147","article-title":"Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in HER2-positive metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: phase III NALA trial","volume":"38","author":"Saura","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.11.006_bib0016","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924002994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924002994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,3]],"date-time":"2025-02-03T12:30:38Z","timestamp":1738585838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924002994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1526820924002994"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.11.006","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adjuvant Trastuzumab Plus Pertuzumab Versus Trastuzumab Alone in Patients Achieving Pathologic Complete Response After Chemotherapy With Trastuzumab and Pertuzumab: A Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}